Whole-body CD8<sup>+</sup> T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

89 ZED88082A in tumor lesions from pre-CART to post-CART Among the 21 evaluable patients, 89 ZED88082A tumor uptake first declined from a geometric mean SUV peak of 4.0 (95%CI [3.3–4.8]) pre-CART to 2.4 (95%CI [1.8–3.3]) post-CART day +5, whereafter an increasing trend to 3.6 (95%CI [2.8–4.7]) post-CART day +7 was observed ( P < 0.01; Fig. 4a , Supplementary Fig. 6a ).

also in 33,188 other papers